Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial
Semaglutide reduced risks of infection SAEs, hospitalization due to infection, and all-cause death with greater benefit among those with poorer glycemic control and greater baseline albuminuria. These findings support potential clinical benefits of semaglutide beyond kidney, CV, and metabolic outcomes in high-risk patients with T2D and CKD.
Authors
- Ole Kleist Jeppesen
- Minh Chau Tran (ORCID: https://orcid.org/0000-0002-0653-1692)
- B. Rayner Rayner
- Nicolas Belmar
- Johannes F E Mann
- K W Mahaffey
- Heidrun Bosch-Traberg
- Richard E Pratley
- Katherine R Tuttle
- Gil Chernin
- Peter Rossing
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Novo Nordisk (Denmark) (DK)
- Providence College (US)
- University of Washington (US)
- Kaplan Medical Center (IL)
- Inland Northwest Health Services (US)
- Groote Schuur Hospital (ZA)
- Translational Research Institute for Metabolism and Diabetes (US)
- Stanford Medicine (US)
- Kidney Centre (PK)
- IT University of Copenhagen (DK)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2026-02-22
- DOI
- https://doi.org/10.1093/ndt/gfag036
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00